Search for Clinical Trial Results

Sponsored By

Dyskeratosis Congenita - 14 Studies Found

Status Study
Active, not recruiting Study Name: SCT for Dyskeratosis Congenita or SAA
Condition:
  • Dyskeratosis Congenita
  • Aplastic Anemia

Date: 2007-03-30
Interventions:
  • Drug: Campath 1H 10, 9, 8, 7,

Recruiting Study Name: Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia
Condition:
  • Dyskeratosis Congenita
  • Aplastic Anemia

Date: 2014-06-10
Interventions:
  • Drug: Alemtuzumab Alemtuzumab

Terminated Study Name: Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita
Condition:
  • Fanconi Anemia
  • Dyskeratosis Congenita

Date: 2009-10-22
Interventions: Drug: danazol Dosage is done according to weight; capsules are 50, 100, 200 mg
Recruiting Study Name: Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita
Condition:
  • Dyskeratosis Congenita
  • Hoyeraal Hreidarss
    Date: 2012-08-06
    Interventions:
    • Biological: alemtuzumab Condit
Completed Study Name: Phase II Pilot Study of Granulocyte Colony-Stimulating Factor for Inherited Bone Marrow Failure Syndromes
Condition:
  • Shwachman Syndrome
  • Fanconi's Anemia

  • Date: 2000-02-24
    Interventions: Drug: filgrastim
Completed Study Name: Assessing Immune Function in Young Patients With Cytopenia That Did Not Respond to Treatment
Condition:
  • Dyskeratosis Congenita
  • Fanconi Anemia
  • Genetic: polymerase chain reaction
  • Other:

Suspended Study Name: Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation
Condition:
  • Thalassemia
  • Sickle Cell Disease
  • Glanzmann Thrombasthenia Date: 2010-09-15
    Interventions: Drug: Alefacept 0.25 mg/kg IV on day -40 and day -39 0.5 mg/kg IV on days -33, -26, -19 and -12 Alefacep
Recruiting Study Name: Familial Investigations of Childhood Cancer Predisposition
Condition:
  • Acute Leukemia
  • Adenomatous Polyposis
  • Adrenocortical Carcin
    Date: 2017-02-08
Recruiting Study Name: Investigation of the Genetics of Hematologic Diseases
Condition:
  • Bone Marrow Failure Syndromes
  • Erythrocyte Disorder
  • Leukocy
    Date: 2016-03-16
Recruiting Study Name: BMT Abatacept for Non-Malignant Diseases
Condition:
  • Hurler Syndrome
  • Fanconi Anemia
  • Glanzmann Thrombasthenia Date: 2013-07-24
    Interventions: Drug: Abatacept All patients will receive 4 doses of abatacept in addition to standard GVHD prophylaxis
Next >>>